S1 Graphical abstract - by Stephanie L. Samani (17896610)

Subjects:

Correlation between myocardial miR levels and stiffness indices. by Stephanie L. Samani (17896610)

Subjects:

miRs with association to LV stiffness indices and functional domain. by Stephanie L. Samani (17896610)

Subjects:

Fold change with steady state myocardial mRNA levels for components of the inflammasome. by Stephanie L. Samani (17896610)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

“…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”

Supplementary Material for: Association of Copeptin, a Surrogate Marker of Arginine Vasopressin, with Decreased Kidney Function in Sugarcane Workers in Guatemala by Butler-Dawson J. (8569992)

WT data of set A398E/V and set M1425V/I pooled for better comparison. by Yousra El Ghaleb (22075892)

Subjects:

sC5b-9 patients decrease in patients treated with mycophenolate mofetil. by Joshua M. Thurman (517193)

“…When analyzed separately based upon treatment, the decrease in sC5b-9 levels was due to a decrease in patients treated with mycophenolate mofetil (P < 0.001 by linear regression; n = 12 for all time-points). …”

Responding Vγ9Vδ2-individuals decreases among HIV-infected patients who present lower Vγ9Vδ2 T-cell number than HD. by Rita Casetti (608635)

Flowability variation after 30mins. by Chenhao Li (822769)

“…SHMP interacted with Ca²⁺, significantly influencing the cement hydration; notably, 1% content resulted a notable reduction of samples from 167.5 kPa to 21.5 kPa at 1 day. …”

Primary cultures of oral fibroblasts from newborn rats incubated for 90 min in medium containing GSNO (a–d) or GSNO-free (e–h). by Maria Adriana Skeff (670466)

Levels of Stt7 Decrease under Prolonged State 1 Conditions and High Light by Sylvain Lemeille (7986)

A647D decreased mexiletine sensitivity of P1332L when coexpressed. by Jie Liu (15128)

Decrease of locomotor activity in <i>Auts2</i> mutant mice during habituation. by Kei Hori (840871)

“…<p>(A) Spontaneous locomotor activity for habituation to the novel environment was measured every 5 min for 60 min. …”

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects: